rs2237886 — KCNQ1 KCNQ1 Potassium Channel Diabetes Variant

KCNQ1 — When the Heart's Potassium Channel Silences the Pancreas

In most people's minds, KCNQ1 is a cardiac gene — mutations in it cause the Long QT syndrome type 1¹¹ Long QT syndrome type 1
A congenital arrhythmia syndrome in which delayed cardiac repolarisation extends the QT interval on ECG, raising ventricular fibrillation risk; the most common inherited cause of sudden cardiac death in young people that strikes young athletes dead on the playing field. But the same Kv7.1 potassium channel is expressed in pancreatic beta cells, where it plays an opposing, subtler role: limiting how much insulin these cells release after a meal. Intronic variants in KCNQ1 — including rs2237886 and the nearby rs2237895, rs2237892, and rs2237897 — emerged from East Asian genome-wide association studies as some of the strongest common-variant signals for type 2 diabetes ever identified. They operate through a peculiar biological mechanism involving genomic imprinting²² genomic imprinting
A form of epigenetic regulation in which the same gene is expressed differently depending on whether it was inherited from the mother or father that makes which parent you inherited the allele from as important as which allele you carry.

The Mechanism

Glucose enters a beta cell, is metabolised to ATP, and the ATP/ADP ratio rise closes ATP-sensitive potassium channels (KATP). The resulting membrane depolarisation opens voltage-gated calcium channels, calcium floods in, and insulin granules dock and fuse with the plasma membrane. KCNQ1 (Kv7.1) generates the slow delayed rectifier current (IKs) that hyperpolarises the cell during the later phase of each depolarisation cycle, essentially acting as a brake on sustained insulin release. When KCNQ1 function is reduced, the brake is released and insulin secretion increases — which is why pharmacological inhibition of KCNQ1 channels enhances glucose-stimulated insulin secretion and raises GLP-1 levels in mice³³ pharmacological inhibition of KCNQ1 channels enhances glucose-stimulated insulin secretion and raises GLP-1 levels in mice
Liu et al. 2014, Islets.

The T2D risk associated with KCNQ1 variants works in the opposite direction. The intronic variants in this region do not alter the Kv7.1 protein itself (rs2237886 is ~11 kb from the nearest exon boundary) but sit within the KCNQ1OT1 imprinting control region⁴⁴ KCNQ1OT1 imprinting control region
A differentially methylated CpG island in KCNQ1 intron 10 that controls imprinted expression of multiple genes in the 11p15 cluster, including Kcnq1ot1 (a long non-coding RNA) and Cdkn1c (a cell-cycle inhibitor regulating beta-cell mass). This regulatory region is maternally methylated and paternally unmethylated. When the risk haplotype is inherited maternally, it disrupts imprinting control, alters Cdkn1c expression in beta cells, and ultimately reduces both beta-cell mass and glucose-stimulated insulin exocytosis.

Rosengren et al. 2012⁵⁵ Rosengren et al. 2012
Reduced insulin exocytosis in human pancreatic beta-cells with gene variants linked to T2D. Diabetes, 2012 showed directly that KCNQ1 risk variants reduce depolarisation-evoked insulin exocytosis and impair granule docking in human beta cells — establishing the cellular defect that accumulates over decades into type 2 diabetes.

The Evidence

KCNQ1 was identified as a T2D gene in the 2008 East Asian GWAS by Unoki et al.⁶⁶ Unoki et al.
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nature Genetics, 2008; initial discovery in 6,967 Japanese subjects, replicated in Singaporean and Danish cohorts. Multiple variants in the same LD block — rs2283228 (OR 1.26, p = 3.1 × 10⁻¹²), rs2237895 (OR 1.32), and rs2237897 (OR 1.41) — all exceeded genome-wide significance. The association is particularly strong in East Asian populations, where the risk haplotype is approximately twice as common as in Europeans (~19% vs ~10% minor allele frequency at the tagging SNPs).

The functional link to insulin secretion was established by Jonsson et al. 2009⁷⁷ Jonsson et al. 2009
A variant in the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin secretion. Diabetes, 2009; 2,830 cases and 3,550 controls plus 16,061 prospective subjects in Swedish and Finnish cohorts, who showed that C-allele carriers at rs2237895 had reduced corrected insulin response, reduced disposition index, and directly reduced glucose-stimulated insulin secretion in isolated human islets. The per-allele OR was 1.23 (95% CI 1.12–1.34).

The imprinting dimension was definitively demonstrated by Hanson et al. 2013⁸⁸ Hanson et al. 2013
Strong parent-of-origin effects in the association of KCNQ1 variants with type 2 diabetes in American Indians. Diabetes, 2013; 7,351 Pima Indians from 4,549 families, who found the maternally-transmitted C-allele at rs2299620 carried an OR of 1.92 (p = 4.1 × 10⁻¹²) with a 28% decrease in insulin secretion, while the paternally-transmitted C-allele showed no significant effect (OR 0.93). This dramatic parent-of-origin asymmetry explains why the association varies across populations and family studies.

rs2237886 itself is an intronic C/T variant with no direct T2D publications in PubMed as of April 2026. Its GWAS associations are with body height (T allele increases height by ~0.04–0.05 SD units across populations) and kidney function markers. However, its position within the KCNQ1 imprinted LD block — which contains all the established T2D risk variants — means the C-allele haplotype at this locus indexes the same molecular risk as the nearby typed variants. Functionally, rs2237886 should be interpreted as a proxy tag for the KCNQ1 T2D haplotype rather than a directly causal variant.

Practical Actions

The KCNQ1 beta-cell defect is a secretory one: after a glucose load, the first-phase insulin spike is attenuated. The cell "sees" the glucose but cannot fully mobilise its insulin stores in response. Over years, this marginal underresponse to meals allows postprandial glucose to remain elevated slightly longer than normal, driving the progression from normal glycaemia to impaired fasting glucose to overt type 2 diabetes.

Two practical consequences follow. First, meal composition matters more for beta-cell-secretion variants than for insulin-resistance variants: reducing postprandial glucose spikes (through lower-glycaemic-index meals, adequate fibre, and protein with each meal) reduces the demand placed on a beta-cell population that cannot respond at full capacity. Second, monitoring fasting glucose and HbA1c is warranted earlier — the KCNQ1 defect accumulates silently over years, and catching impaired fasting glucose before overt T2D enables effective prevention.

Interactions

The KCNQ1 T2D locus interacts with maternal inheritance: the same C-allele haplotype that confers OR 1.92 when maternally inherited appears neutral when paternally inherited (Hanson et al. 2013). This means a parent with KCNQ1 risk who is female passes a substantially higher T2D risk to her children than a father with the same genotype. This is one of the clearest examples of imprinting influencing common disease risk in humans.

Pathway-level interactions: KCNQ1's insulin-secretion defect compounds with variants affecting insulin resistance (TCF7L2 rs7903146, PPARG rs1801282) and beta-cell mass (CDKAL1 rs7756992, CDKN2A/B locus). Individuals carrying both a KCNQ1 secretion defect and an insulin resistance variant face dual pressure on glucose homeostasis. Similarly, the KCNQ1 channel interacts directly with KCNE1 (rs1805127) and KCNE2 proteins that modulate IKs current density — variants in these accessory subunits could amplify or attenuate the beta-cell phenotype.